Precision BioSciences (DTIL) Set to Announce Quarterly Earnings on Monday

Precision BioSciences (NASDAQ:DTIL – Get Rating) will be announcing its earnings results before the market opens on Monday, August 8th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.

Precision BioSciences (NASDAQ:DTIL – Get Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.12. The business had revenue of $3.32 million during the quarter, compared to the consensus estimate of $5.00 million. Precision BioSciences had a negative net margin of 39.10% and a negative return on equity of 44.19%. During the same quarter last year, the firm posted ($0.33) EPS. On average, analysts expect Precision BioSciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Stock Performance

Shares of DTIL opened at $1.74 on Friday. The company has a 50-day simple moving average of $1.54 and a 200-day simple moving average of $2.68. The company has a quick ratio of 4.61, a current ratio of 4.61 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $108.19 million, a PE ratio of -2.60 and a beta of 1.58. Precision BioSciences has a 52-week low of $1.11 and a 52-week high of $14.38.

Analyst Ratings Changes

Several research firms have weighed in on DTIL. BMO Capital Markets began coverage on shares of Precision BioSciences in a report on Thursday, June 16th. They set an “outperform” rating and a $7.00 target price for the company. William Blair downgraded shares of Precision BioSciences from an “outperform” rating to a “market perform” rating in a report on Thursday, June 9th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Precision BioSciences in a report on Thursday, June 23rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $15.60.

Insider Buying and Selling

In other Precision BioSciences news, CFO John Alexander Kelly purchased 33,784 shares of Precision BioSciences stock in a transaction on Wednesday, June 22nd. The shares were purchased at an average cost of $1.50 per share, with a total value of $50,676.00. Following the completion of the transaction, the chief financial officer now directly owns 117,701 shares in the company, valued at approximately $176,551.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Precision BioSciences news, CFO John Alexander Kelly bought 33,784 shares of the stock in a transaction on Wednesday, June 22nd. The stock was purchased at an average price of $1.50 per share, for a total transaction of $50,676.00. Following the completion of the purchase, the chief financial officer now directly owns 117,701 shares in the company, valued at $176,551.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Derek Jantz sold 18,849 shares of the business’s stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $2.06, for a total transaction of $38,828.94. Following the transaction, the insider now directly owns 4,055,174 shares of the company’s stock, valued at approximately $8,353,658.44. The disclosure for this sale can be found here. Corporate insiders own 8.50% of the company’s stock.

Institutional Investors Weigh In On Precision BioSciences

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in shares of Precision BioSciences by 1,044.0% in the first quarter. Renaissance Technologies LLC now owns 233,376 shares of the company’s stock valued at $719,000 after acquiring an additional 212,976 shares during the period. Federated Hermes Inc. boosted its holdings in Precision BioSciences by 167.1% during the first quarter. Federated Hermes Inc. now owns 182,744 shares of the company’s stock worth $563,000 after buying an additional 114,337 shares during the last quarter. Prudential Financial Inc. acquired a new stake in shares of Precision BioSciences during the first quarter worth about $455,000. Swiss National Bank raised its position in Precision BioSciences by 9.5% in the 1st quarter. Swiss National Bank now owns 114,900 shares of the company’s stock valued at $354,000 after buying an additional 10,000 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in Precision BioSciences in the 1st quarter valued at approximately $291,000. Institutional investors own 51.65% of the company’s stock.

Precision BioSciences Company Profile

(Get Rating)

Precision BioSciences, Inc, a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.